104 related articles for article (PubMed ID: 27272813)
1. Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature.
Grisanti S; Antonelli A; Buglione M; Almici C; Foroni C; Sodano M; Triggiani L; Greco D; Palumbo C; Marini M; Magrini SM; Berruti A; Simeone C
Anticancer Res; 2016 Jun; 36(6):2975-81. PubMed ID: 27272813
[TBL] [Abstract][Full Text] [Related]
2. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
Aragon-Ching JB; Siegel RS; Frazier H; Andrawis R; Hendricks F; Phillips M; Jarrett T; Guebre-Xabiher H; Patierno S; Simmens SJ
Clin Genitourin Cancer; 2015 Oct; 13(5):e341-5. PubMed ID: 25956468
[TBL] [Abstract][Full Text] [Related]
4. Very low rate of circulating tumour cells (CTCs) in patients with PSA recurrence after radical prostatectomy referred to salvage radiotherapy.
Gunnlaugsson A; Nilsson P; Kjellén E; Blom R
Acta Oncol; 2016; 55(1):113-5. PubMed ID: 25920362
[No Abstract] [Full Text] [Related]
5. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen.
Miyake H; Hara I; Kurahashi T; Muramaki M; Yamanaka K; Inoue TA; Fujisawa M
Urol Int; 2006; 77(3):200-4. PubMed ID: 17033205
[TBL] [Abstract][Full Text] [Related]
6. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
[TBL] [Abstract][Full Text] [Related]
7. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
8. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy.
Lowe BA; Lieberman SF
J Urol; 1997 Oct; 158(4):1452-6. PubMed ID: 9302141
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
10. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
11. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
13. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
14. Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease.
Corcoran NM; Hovens CM; Metcalfe C; Hong MK; Pedersen J; Casey RG; Peters J; Harewood L; Goldenberg SL; Costello AJ; Gleave ME
BJU Int; 2012 Sep; 110(6):821-7. PubMed ID: 22257140
[TBL] [Abstract][Full Text] [Related]
15. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy.
Lowes LE; Lock M; Rodrigues G; D'Souza D; Bauman G; Ahmad B; Venkatesan V; Allan AL; Sexton T
Clin Transl Oncol; 2012 Feb; 14(2):150-6. PubMed ID: 22301405
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
Pruthi RS; Johnstone I; Tu IP; Stamey TA
Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
[TBL] [Abstract][Full Text] [Related]
18. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
[TBL] [Abstract][Full Text] [Related]
19. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
[TBL] [Abstract][Full Text] [Related]
20. Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
Thalgott M; Rack B; Horn T; Heck MM; Eiber M; Kübler H; Retz M; Gschwend JE; Andergassen U; Nawroth R
Anticancer Res; 2015 Oct; 35(10):5679-85. PubMed ID: 26408743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
